Investment Stage

Focus Areas

About Investor

Bert Vogelstein is a Venture Partner at Catalio Capital Management, a healthcare-focused investment firm, while continuing his primary academic role as Co-Director of the Ludwig Center at Johns Hopkins Medicine. As an investor, he is associated with early-stage biotech and diagnostics companies at seed and Series A, generally in the $100K–$5.0M range. He is one of the world’s most cited cancer researchers, known for foundational work on the genetics of colorectal cancer and tumor-suppressor genes. His lab’s discoveries have underpinned multiple venture-backed companies in early cancer detection and oncology therapeutics that Catalio has financed.